Ameriprise’s Decoy Therapeutics DCOY Stock Holding History

Ameriprise’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Hold	0	–	-$88K	–	3761
2018 Q4	–	Hold	0	–	–	–	3540
2018 Q3	–	Hold	0	–	–	–	3603
2018 Q2	–	Sell	-1	Closed	-$3.43M	–	3413
2018 Q1	$4.13M	Hold	1	–	–	﹤0.01%	2305
2017 Q4	$2.92M	Hold	1	–	–	﹤0.01%	2459
2017 Q3	$2.46M	Hold	1	–	–	﹤0.01%	2508
2017 Q2	$2.52M	Buy	+1	New	+$3.26M	﹤0.01%	2494
2017 Q1	–	Sell	-1	Closed	-$4.08M	–	2655
2016 Q4	$3.82M	Hold	1	–	–	﹤0.01%	2257
2016 Q3	$9.22M	Hold	1	–	–	0.01%	1517
2016 Q2	$9.43M	Hold	1	–	–	0.01%	1440
2016 Q1	$9.18M	Hold	1	–	–	0.01%	1485
2015 Q4	$7.66M	Hold	1	–	–	﹤0.01%	1672
2015 Q3	$7.24M	Hold	1	–	–	﹤0.01%	1708
2015 Q2	$8.11M	Hold	1	–	–	﹤0.01%	1765
2015 Q1	$9.44M	Buy	+1	New	+$15.5M	0.01%	1605

Other funds holding DCOY

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AIP

Ahrens Investment Partners Lafayette, Louisiana $202M AUM 3.91% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Ameriprise's DCOY Position: Q1 2019 in Review

Ameriprise held its Decoy Therapeutics (DCOY) position steady in Q1 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3761.

Ameriprise first reported a position in DCOY in Q1 2015 and has held it in 12 quarters since. The position peaked at $9.44M in Q1 2015. 1 fund tracked by Wall St. Rank holds DCOY as of Q1 2019.

Ameriprise held 0 shares of Decoy Therapeutics worth $0 as of Q1 2019.
Ameriprise left its Decoy Therapeutics share count unchanged in Q1 2019.
Decoy Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2019, its #3761 holding.
Ameriprise first reported a position in Decoy Therapeutics in Q1 2015 and has held it in 12 quarters since.
Ameriprise's Decoy Therapeutics position peaked at $9.44M in Q1 2015.
1 fund tracked by Wall St. Rank held Decoy Therapeutics as of Q1 2019.

Based on Ameriprise's 13F filing for Q1 2019, filed 15 May 2019.